Evidence map›Paper›PMID 38066426›Full record

ArticleBMC microbiology2023

Rapid intestinal and systemic metabolic reprogramming in an immunosuppressed environment.

Bing Ma, Samuel J Gavzy, Michael France, Yang Song, Hnin Wai Lwin, Allison Kensiski, Vikas Saxena, Wenji Piao, Ram Lakhan, Jegan Iyyathurai and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Bing MaInstitute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. BMa@som.umaryland.edu.
Samuel J GavzyDepartment of Surgery, University of Maryland Medical Center, Baltimore, MD, 21201, USA.
Michael FranceInstitute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Yang SongInstitute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Hnin Wai LwinInstitute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Allison KensiskiCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Vikas SaxenaCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Wenji PiaoCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Ram LakhanCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Jegan IyyathuraiCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Lushen LiCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Christina PaluskieviczCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Long WuCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Marina WillsonShirkeyCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Emmanuel F MongodinInstitute of Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Valeria R MasDepartment of Surgery, University of Maryland Medical Center, Baltimore, MD, 21201, USA.
Jonathan S BrombergDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. JBromberg@som.umaryland.edu.
University of Maryland, Baltimore · USNational Heart Lung and Blood Institute · US

Funding

Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Signaling Pathways in Innate ImmunityT32AI095190 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Stefanie N. Vogel · 2012 to 2026
$4.7M
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcomeR01HL148672 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BROMBERG, JONATHAN S, MA, BING · 2019 to 2022
$2.3M
Mechanisms of microbiome-driven cardiac allograft outcomesU01AI170050 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Jonathan S Bromberg, Bing Ma · 2022 to 2026
$1.9M
NCI NIH HHS T32 CA154274NHLBI NIH HHS R01 HL148672NHLBI NIH HHS R01HL148672NIAID NIH HHS T32 AI095190NIAID NIH HHS U01 AI170050
6 · The paper itself

Abstract

Intrinsic metabolism shapes the immune environment associated with immune suppression and tolerance in settings such as organ transplantation and cancer. However, little is known about the metabolic activities in an immunosuppressive environment. In this study, we employed metagenomic, metabolomic, and immunological approaches to profile the early effects of the immunosuppressant drug tacrolimus, antibiotics, or both in gut lumen and circulation using a murine model. Tacrolimus induced rapid and profound alterations in metabolic activities within two days of treatment, prior to alterations in gut microbiota composition and structure. The metabolic profile and gut microbiome after seven days of treatment was distinct from that after two days of treatment, indicating continuous drug effects on both gut microbial ecosystem and host metabolism. The most affected taxonomic groups are Clostriales and Verrucomicrobiae (i.e., Akkermansia muciniphila), and the most affected metabolic pathways included a group of interconnected amino acids, bile acid conjugation, glucose homeostasis, and energy production. Highly correlated metabolic changes were observed between lumen and serum metabolism, supporting their significant interactions. Despite a small sample size, this study explored the largely uncharacterized microbial and metabolic events in an immunosuppressed environment and demonstrated that early changes in metabolic activities can have significant implications that may serve as antecedent biomarkers of immune activation or quiescence. To understand the intricate relationships among gut microbiome, metabolic activities, and immune cells in an immune suppressed environment is a prerequisite for developing strategies to monitor and optimize alloimmune responses that determine transplant outcomes.

Indexed as

TacrolimusAnimalsImmunosuppressive AgentsMetabolomeMetabolomicsMiceImmunosuppressive AgentsTacrolimusAntibioticsGut dysbiosisGut microbiomeImmune toleranceImmunosuppressionIntegrative multi-omicsMetabolomeTransplantation

Identifiers

PMID38066426
PMCPMC10709923
OpenAlexW4389508743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.